Transdermal drug delivery has gained a solid market position in a few specialty markets, owing to the unique advantages it provides in selected therapeutic applications. Now these advantages are beginning to inure to a class of conditions that are particularly well-suited to the major benefits of transdermal drug administration.

The FDA recalled Tuesday all the patches (25-microgram-per-hour patches with expiration dates on or before December 2009) containing fentanyl, because it can have a serious defect.

Greystone Associates Analyzes the Impact of Generics, Post-launch Complications, and New Transdermal Products on Demand and Revenue.